The transcontinental variability of nonalcoholic fatty liver disease

Abstract

Aim: To compare the phenotype of lean versus overweight (OW) and obese (OB) subjects with non-alcoholic fatty liver disease (NAFLD) across multiple continents.

Methods: A retrospective study of histologically defined subjects from a single center each in France (Fr), Brazil (Br), India (In) and United States (US) was performed.

Results: A total of 70 lean [body mass index (BMI) < 25 kg/m²] subjects (Fr:Br:In:US: 16:19:22:13) with NAFLD were compared to 136 OW (BMI > 25 kg/m², BMI < 29 kg/m²) (n = 28:33:52:23) and 224 OB subjects (BMI > 29 kg/m²) (n = 81:11:22:103). Lean French subjects had the lowest incidence of type 2 diabetes while those from Brazil (P < 0.01) had the highest. Lean subjects had similar low-density lipoprotein-cholesterol, but higher high-density lipoprotein-cholesterol compared to obese subjects in all regions. In both lean and obese subjects, there were both insulin-sensitive and insulin-resistant subjects. Lean French subjects were most insulin-sensitive while those from Brazil were mostly insulin-resistant. For each weight category, subjects from India were more insulin-sensitive than those from other regions. Disease activity increased from lean to overweight to obese in France but was similar across weight categories in other regions.

Conclusion: The phenotype of NAFLD in lean subjects varies by region. Some obese subjects with NAFLD are insulin-sensitive. We hypothesize that genetics and region-specific disease modifiers account for these differences.

Keywords

Non-alcoholic fatty liver disease / phenotype / epidemiology / demographics

References

[1] Dulai PS,Patel J,Prokop LJ.Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis..Hepatology2017;65:1557-65 PMCID:PMC5397356

[2] Wong RJ,Cheung R,Harrison SA.Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States..Gastroenterology2015;148:547-55

[3] Leite NC,Araujo AL,Cardoso CR.Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus..Liver Int2009;29:113-9

[4] Ercin CN,Genc H,Aslan F.Insulin resistance but not visceral adiposity index is associated with liver fibrosis in nondiabetic subjects with nonalcoholic fatty liver disease..Metab Syndr Relat Disord2015;13:319-25

[5] Dumas ME,Nicholson JK.Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease..Gastroenterology2014;146:46-62

[6] Feng RN,Wang C,Liu LY.Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population..World J Gastroenterol2014;20:17932-40 PMCID:PMC4273143

[7] Akyuz U,Yilmaz Y.Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels..Scand J Gastroenterol2015;50:341-6

[8] Younossi ZM,Negro F,Younossi Y.Nonalcoholic fatty liver disease in lean individuals in the United States..Medicine (Baltimore)2012;91:319-27

[9] Margariti E,Manolakopoulos S.Non-alcoholic fatty liver disease may develop in individuals with normal body mass index..Ann Gastroenterol2012;25:45-51 PMCID:PMC3959339

[10] Das K.Lean NASH: distinctiveness and clinical implication..Hepatol Int.2013;7 Suppl 2:806-13

[11] Younossi ZM,Rafiq N,Younoszai Z.Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality..Hepatology2011;53:1874-82

[12] Kleiner DE,Van Natta M,Contos MJ.Design and validation of a histological scoring system for nonalcoholic fatty liver disease..Hepatology2005;41:1313-21

[13] Expert panel on detection, evaluation, and treatment of high blood cholesterol in adultsExecutive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)..JAMA2001;285:2486-97

[14] Misra A.Revisions of cutoffs of body mass index to define overweight and obesity are needed for the Asian-ethnic groups..Int J Obes Relat Metab Disord2003;27:1294-6

[15] Misra A,Makkar BM,Wasir JS.Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management..J Assoc Physicians India2009;57:163-70

[16] Ascaso JF,Real JT,Priego A.Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism..Diabetes Care2003;26:3320-5

[17] Bugianesi E,Vanni E,Cassader M.Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms..Diabetologia2005;48:634-42

[18] Arata M,Nishimata S,Kawashima H.Nonalcoholic steatohepatitis and insulin resistance in children..World J Diabetes2014;5:917-23 PMCID:PMC4265881

[19] Menke A,Geiss L.Prevalence of and trends in diabetes among adults in the United States, 1988-2012..JAMA2015;314:1021-9

[20] Cho NH,Karuranga S,da Rocha Fernandes JD.IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045..Diabetes Res Clin Pract2018;138:271-81

[21] Matta J,Rives Lange C.French and worldwide epidemiology of obesity..Presse Med2018;47:434-8

[22] Martins-Silva T,Mola CL,Tovo-Rodrigues L.Prevalence of obesity in rural and urban areas in Brazil: national health survey, 2013..Rev Bras Epidemiol2019;22:e190049

[23] Ng M,Robinson M,Graetz N.Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013..Lancet2014;384:766-81 PMCID:PMC4624264

[24] Malta DC,Machado Í,Azeredo C.Prevalence of arterial hypertension according to different diagnostic criteria, national health survey..Rev Bras Epidemiol2018;21:e180021

[25] UN Food and Agricultural Organization FAOstat food balance sheets. Chapter 3: Calculation Of The Energy Content Of Foods - Energy Conversion Factors. Food and Agriculture Organization of the United Nations. Available from: http://www.fao.org/docrep/006/Y5022E/y5022e04.htm. [Last accessed on 24 Sep 2020]

[26] Duncan GE.The “fit but fat” concept revisited: population-based estimates using NHANES..Int J Behav Nutr Phys Act2010;7:47 PMCID:PMC2885314

[27] Pacana T.Vitamin E and nonalcoholic fatty liver disease..Curr Opin Clin Nutr Metab Care2012;15:641-8 PMCID:PMC4984672

[28] Sanyal AJ,Kowdley KV,Diehl AM.Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis..N Engl J Med2010;362:1675-85 PMCID:PMC2928471

[29] Borai A,Ferns GA.The biochemical assessment of insulin resistance..Ann Clin Biochem2007;44:324-42

[30] Younossi ZM,Ong J,AlQahtani S.Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States..Clin Gastroenterol Hepatol2020;

[31] Vilar L,Faintuch J,Nogueira MA.High-fat diet: a trigger of non-alcoholic steatohepatitis? Preliminary findings in obese subjects..Nutrition2008;24:1097-102

[32] Mazo DF,Stefano JT,Gomes-Gouvea MS.Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population..Ann Hepatol2019;18:466-71

[33] Duarte SMB,Miele L,Souza-Basqueira M.Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: a prospective pilot study..Nutr Metab Cardiovasc Dis2018;28:369-84